statistiche ricercatore

statistiche per SARTORE BIANCHI, ANDREA

Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3772
EU - Europa 2803
AS - Asia 2371
OC - Oceania 145
SA - Sud America 94
AF - Africa 62
Continente sconosciuto - Info sul continente non disponibili 22
Totale 9269
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3630
CN - Cina 1481
IT - Italia 1077
DE - Germania 399
GB - Regno Unito 397
JP - Giappone 212
FR - Francia 195
KR - Corea 149
AU - Australia 129
CA - Canada 117
IN - India 105
TW - Taiwan 94
NL - Olanda 89
ES - Italia 86
IE - Irlanda 64
RO - Romania 59
RU - Federazione Russa 51
TR - Turchia 50
HK - Hong Kong 48
BE - Belgio 47
IR - Iran 47
CZ - Repubblica Ceca 46
BR - Brasile 44
NO - Norvegia 39
SE - Svezia 38
ZA - Sudafrica 38
PT - Portogallo 34
PL - Polonia 28
GR - Grecia 27
CH - Svizzera 26
IL - Israele 26
ID - Indonesia 25
UA - Ucraina 25
CL - Cile 21
MY - Malesia 20
SG - Singapore 20
VN - Vietnam 20
TH - Thailandia 19
AT - Austria 15
MX - Messico 15
NZ - Nuova Zelanda 15
AP - ???statistics.table.value.countryCode.AP??? 14
DK - Danimarca 14
CO - Colombia 12
JO - Giordania 11
HU - Ungheria 10
PE - Perù 9
FI - Finlandia 8
PK - Pakistan 8
SK - Slovacchia (Repubblica Slovacca) 8
AR - Argentina 7
EU - Europa 6
MA - Marocco 6
EG - Egitto 5
IQ - Iraq 5
RS - Serbia 5
SA - Arabia Saudita 5
BA - Bosnia-Erzegovina 4
DZ - Algeria 4
KW - Kuwait 4
LK - Sri Lanka 4
LT - Lituania 4
PH - Filippine 4
DO - Repubblica Dominicana 3
QA - Qatar 3
A1 - ???statistics.table.value.countryCode.A1??? 2
BG - Bulgaria 2
CY - Cipro 2
GE - Georgia 2
HR - Croazia 2
KE - Kenya 2
LB - Libano 2
LV - Lettonia 2
PA - Panama 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BD - Bangladesh 1
BM - Bermuda 1
CR - Costa Rica 1
ET - Etiopia 1
GT - Guatemala 1
GU - Guam 1
IM - Isola di Man 1
JM - Giamaica 1
KH - Cambogia 1
MO - Macao, regione amministrativa speciale della Cina 1
NE - Niger 1
NG - Nigeria 1
PR - Porto Rico 1
SD - Sudan 1
SI - Slovenia 1
SN - Senegal 1
UY - Uruguay 1
Totale 9269
Salva come PNG Salva come JPEG
Città #
Fairfield 507
Milan 480
Houston 375
Woodbridge 281
Seattle 275
Buffalo 231
Beijing 219
Shanghai 197
Ann Arbor 192
Ashburn 182
Cambridge 173
Guangzhou 125
Wilmington 124
Wuhan 100
Nanjing 70
Hangzhou 65
Taipei 65
Chengdu 63
Tokyo 60
Dublin 44
Seoul 41
San Diego 39
Southend 37
Las Vegas 36
Ottawa 36
Nürnberg 35
Shenyang 35
Torino 33
Changsha 31
Muizenberg 30
New York 29
Clearwater 28
Central District 27
London 27
Changchun 26
Munich 25
Phoenix 25
Rome 25
Los Angeles 24
Oslo 23
Chicago 22
Jakarta 22
Rochester 21
Jinan 20
Heidelberg 19
Berlin 18
Norwalk 18
Boston 16
Melbourne 16
Milpitas 16
Redmond 16
University Park 16
Zhengzhou 16
Duncan 15
Madrid 15
Baltimore 14
Harbin 14
Leawood 14
San Francisco 14
Fuzhou 13
Padova 13
San Jose 13
Tianjin 13
Toronto 13
Amsterdam 12
Dallas 12
Mumbai 12
Riva 12
Singapore 12
Barcelona 11
Brisbane 11
Chongqing 11
Dong Ket 11
Hefei 11
Mountain View 11
Nanchang 11
New Delhi 11
Bangalore 10
Fontenay-sous-bois 10
Istanbul 10
Lanzhou 10
Lima 10
Newbury Park 10
Philadelphia 10
Provo 10
Bucharest 9
Guiyang 9
Henderson 9
Madison 9
Nutley 9
San Mateo 9
Bari 8
Birmingham 8
Darmstadt 8
Durham 8
Leicester 8
Nanning 8
Nashville 8
Oxford 8
Paris 8
Totale 5181
Salva come PNG Salva come JPEG
Nome #
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer, file 509086 1808
Liquid biopsy for rectal cancer: a systematic review, file 1300031 969
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer, file 509105 574
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets, file 481585 523
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer : the 'BRAF BeCool' study, file 1280213 417
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy, file 1485851 301
Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas, file 1713979 293
Early-onset colorectal cancer in young individuals, file 1211176 229
Third- or Later-line Therapy for Metastatic Colorectal Cancer : Reviewing Best Practice, file 1201003 226
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib : combined results from two phase I trials (ALKA-372-001 and STARTRK-1), file 970760 221
Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy, file 1777142 181
Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy, file 1384064 170
The DNA Damage Response pathway as a land of therapeutic opportunities for colorectal cancer, file 1485845 159
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients, file 480425 154
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer, file 481528 149
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer, file 966422 145
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case, file 969065 137
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer, file 1389529 135
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study), file 1052971 133
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types, file 665103 133
Increased incidence of colon cancer among individuals younger than 50 years : a 17 years analysis from the cancer registry of the municipality of Milan, Italy, file 1231568 126
Challenging chemoresistant metastatic colorectal cancer: Therapeutic strategies from the clinic and from the laboratory, file 1396048 123
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer, file 1032632 120
Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility : a Single-Institution Experience, file 966361 113
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer, file 688493 107
Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in kras-mutant metastatic colorectal cancer, file 482463 105
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer, file 1016542 102
Concurrent small cell transformation and emergence of trans-C797S and T790M mutations under sequential treatment with EGFR inhibitors in lung adenocarcinoma, file 1401967 101
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies, file 1102082 96
The right chance for temozolomide in metastatic colorectal cancer?, file 1193830 95
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer, file 1310473 89
Mutation-enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced cancers, file 967143 89
Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy, file 1552650 88
Central Nervous System as Possible Site of Relapse in ERBB2-PositiveMetastatic Colorectal Cancer:Long-term Results of TreatmentWith Trastuzumab and Lapatinib, file 1462770 82
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib, file 1356267 80
Bortezomib inhibits nuclear factor-κB-dependent survival and has potent in vivo activity in mesothelioma, file 1201027 78
Clonal evolution andKRAS-METcoamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer, file 970778 75
The quest for improving treatment of cancer of unknown primary (CUP) through molecularly-driven treatments: a systematic review, file 1473630 64
Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients, file 1347993 62
Gemcitabine and Oxaliplatin in the Treatment of Patients with Immunotherapy-Resistant Advanced Renal Cell Carcinoma: Final Results of a Single-Institution Phase II Study, file 1201288 51
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial, file 1569432 42
Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial, file 1266896 38
Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases, file 1632846 37
Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: Learning from a clinical case (ESMO Open (2018) 3 (e000299) DOI: 10.1136/esmoopen-2017-000299), file 1402969 35
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions, file 1555301 35
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer, file 489182 33
Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature, file 1693156 28
The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer, file 1370621 24
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer, file 507386 22
A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin, file 1811700 20
The evolutionary landscape of treatment for BRAFv600e mutant metastatic colorectal cancer, file 1863142 20
Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer, file 480398 20
Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer, file 1193679 18
Strategies to tackle RAS-mutated metastatic colorectal cancer, file 1863096 15
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies, file 1863226 14
The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer, file 1863124 13
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer, file 1863283 13
Assessment of a HER2 scoring system for colorectal cancer : results from a validation study, file 480370 13
The genomic landscape of response to EGFR blockade in colorectal cancer, file 480448 12
Breaking Barriers in HER2+ Cancers, file 1549316 11
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients, file 559301 11
Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer : multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR, file 1015009 10
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA, file 1863112 10
Raccomandazioni per l’esecuzione di indagini molecolari su biopsia liquida in oncologia, file 1863275 9
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor, file 966988 9
Empowering clinical decision making in oligometastatic colorectal cancer: The potential role of drug screening of patient-derived organoids, file 1863079 8
Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast, file 650595 8
Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge : Single Institution Series and Systematic Review Study, file 1014267 7
A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin, file 1381193 7
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer, file 489305 7
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, file 559310 7
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth, file 965293 7
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression, file 1193796 6
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES) : a proof-of-concept, multicentre, open-label, phase 2 trial, file 676532 6
Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET), file 966392 6
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients, file 966451 6
Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET), file 1017555 5
Mutation-enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced cancers, file 1018773 5
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer : results from a pooled-analysis of the Valentino and TRIBE first-line trials, file 1570520 5
Mechanisms of immune escape and resistance to checkpoint inhibitor therapies in mismatch repair deficient metastatic colorectal cancers, file 1863059 5
Acquired resistance to EGFR-targeted therapies incolorectal cancer, file 481642 5
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to Anti-EGFR therapies in colorectal cancer, file 489250 5
Detection of circulating tumor DNA in early- and late-stage human malignancies, file 489265 5
Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer, file 509266 5
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer, file 549420 5
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer, file 556391 5
Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge : Single Institution Series and Systematic Review Study, file 968893 5
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer, file 1014733 4
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer, file 1359227 4
Adaptive mutability of colorectal cancers in response to targeted therapies, file 1385122 4
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01) : a multicentre, open-label, phase 2 trial, file 1795406 4
Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression, file 1813130 4
Relationships Between Köhne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer, file 1863288 4
Liquid biopsy for small cell lung cancer either de novo or transformed: Systematic review of different applications and meta-analysis, file 1912302 4
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis, file 481492 4
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System, file 489201 4
Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer, file 489312 4
Standardisation of EGFR FISH in colorectal cancer: Results of an international interlaboratory reproducibility ring study, file 507431 4
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer, file 559746 4
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer, file 676893 4
Totale 9597
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9708
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9708
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2016/201778 0000 00 32 534718
2017/2018727 28376141 4429 5061 601619065
2018/20191290 77788176 6967 8371 103139240206
2019/20202267 187159143170 189183 197213 252194172208
2020/20212775 154189203187 246216 225191 254349295266
2021/20222384 301321306532 462232 2300 0000
Totale 9708
 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie
Logo CINECA  Copyright © 2022